Pfizer's $5.4 Billion Investment in GBT Falls Short Once More as Sickle Cell Treatment Stumbles in Phase III Trials

Pfizer’s $5.4 Billion Investment in GBT Falls Short Once More as Sickle Cell Treatment Stumbles in Phase III Trials

Pfizer's $5.4 Billion Investment in GBT Falls Short Once More as Sickle Cell Treatment Stumbles in Phase III Trials